Streetbeat News

VANI

Vivani Medical, Inc.

https://www.vivani.com

Industry

Medical - Devices

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Open

1.09

Mkt cap

65M

Volume

60K

High

1.10

P/E Ratio

-2.56

52-wk high

2.22

Low

1.08

Div yield

N/A

52-wk low

1.03

Novo Nordisk's diabetes and obesity drugs, Ozempic and Wegovy, are now listed as available by the FDA, potentially ending their shortage status. This could impact compounding pharmacies and patients who rely on compounded versions of these drugs.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:52 pm

Vivani Medical (NASDAQ:VANI) has received approval for a clinical trial in Australia for its obesity treatment implant. The trial will assess the safety and efficacy of the exenatide NanoPortal implant, with data expected in 2025. Vivani aims to use the trial data for regulatory submissions globally.

Portfolio Pulse from Vandana Singh

September 26, 2024 | 12:00 pm

Vivani Medical announced that their upcoming study will be the first clinical application of their NanoPortal drug implant platform technology. This marks a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:00 pm

Vivani Medical has received regulatory approval to start its first human clinical trial for a GLP-1 implant targeting obesity and overweight conditions in Australia.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:00 pm

Vivani Medical (NASDAQ:VANI) reported positive preclinical results for its exenatide implant, showing significant liver fat reduction in obese mice. The implant, which could be a promising treatment for obesity, is set to begin clinical trials in late 2024. The news led to a 7.32% increase in VANI's stock price.

Portfolio Pulse from Vandana Singh

September 04, 2024 | 11:33 am

Vivani Medical announced that the clinical development of its exenatide implant for overweight and obese patients is on track to begin in Q4 2024 as part of its NPM-115 program.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:30 am

Vivani Medical announced that its GLP-1 (exenatide) implant achieved an 82% reduction in liver fat in an obese mouse model with a single administration, suggesting potential for twice-yearly dosing.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:30 am

Vivani Medical has announced preclinical results for its miniature, ultra long-acting GLP-1 implant, which targets liver fat reduction. This development could have implications for the company's future product offerings and market position.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:30 am

Vivani Medical (NASDAQ:VANI) reported a Q2 2024 adjusted EPS of $(0.10), beating the analyst consensus estimate of $(0.12) by 16.67%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:23 pm

Insiders are buying shares of Pineapple Financial Inc. (NYSE:PAPL) and Vivos Inc. (OTC:RDGL), indicating confidence in these companies despite recent challenges. Pineapple Financial's CSO bought 2,000 shares after a wider-than-expected quarterly loss, while Vivos' CEO acquired 50,000 shares following an FDA application for human clinical trials.

Portfolio Pulse from Avi Kapoor

August 05, 2024 | 1:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.